Chinese herbal medicine use and risk of end-stage renal disease in patients with chronic kidney disease: is there an immortal time bias?

Kidney International

Volumn 90, Issue 1, 2016, Pages 227-228

  Hu, Yu Wen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT;

CHINESE MEDICINE; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG USE; END STAGE RENAL DISEASE; HUMAN; IMMORTAL TIME; LETTER; PRIORITY JOURNAL; RISK; RISK REDUCTION; SURVIVAL; TIME; TREATMENT DURATION; CHRONIC KIDNEY FAILURE; STATISTICAL BIAS;

BIAS; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; RISK;

EID: 84988336030     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.03.044     Document Type: Letter

References (4)

1. 1 Lin, M.-Y., Chiu, Y.-W., Chang, J.-S., et al. Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int 88 (2015), 1365–1373.
2. 2 Suissa, S., Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167 (2008), 492–499.
3. 3 Liu, J., Weinhandl, E.D., Gilbertson, D.T., et al. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney Int 81 (2012), 341–350.
4. 4 Wang, M.-C., Hazards regression analysis for length-biased data. Biometrika 83 (1996), 343–354.